Literature DB >> 33291177

[Liver-specific diagnostic for non-alcoholic fatty liver disease (NAFLD) - time to replace liver biopsy?]

Maurice Michel1, Jörn M Schattenberg1.   

Abstract

Non-alcoholic fatty liver disease (NAFLD) is one of the most common liver diseases. In Germany, the prevalence in the adult population is estimated at 24 % and the incidence is increasing. Prognostically, the distinction between early and advanced stages of the disease is important. In particular, the extent of scarring considered as liver fibrosis is of prognostic significance. Patients with advanced fibrosis and cirrhosis show increased mortality. Liver fibrosis develops as a consequence of a persistent inflammation of the liver tissue over time. Since inflammation and fibrosis are histological features, liver biopsy is considered the reference method in the diagnosis of NAFLD. More recently, non-invasive diagnostic methods for staging (of fibrosis) and grading (activity) of the disease are being developed and validated. The current review summarizes new developments in non-invasive liver diagnostics. Thieme. All rights reserved.

Entities:  

Mesh:

Year:  2020        PMID: 33291177     DOI: 10.1055/a-1291-8483

Source DB:  PubMed          Journal:  Z Gastroenterol        ISSN: 0044-2771            Impact factor:   2.000


  4 in total

1.  Significant liver fibrosis is a predictor of poor health-related quality of life in people living with HIV.

Authors:  Maurice Michel; Alisha Wahl; Malena Anders; Saleh A Alqahtani; Wolfgang M Kremer; Peter R Galle; Christian Labenz; Daniel Grimm; Martin Sprinzl; Jörn M Schattenberg
Journal:  Qual Life Res       Date:  2022-08-22       Impact factor: 3.440

2.  Prevalence and Risk Factors of Advanced Liver Fibrosis in a Population-Based Study in Germany.

Authors:  Karl J Lackner; Jörn M Schattenberg; Yvonne Huber; Andreas Schulz; Irene Schmidtmann; Manfred Beutel; Norbert Pfeiffer; Thomas Münzel; Peter R Galle; Philipp S Wild
Journal:  Hepatol Commun       Date:  2022-02-05

3.  Prevalence and risk factors of nonalcoholic steatohepatitis with significant fibrosis in people with HIV.

Authors:  Maurice Michel; Christian Labenz; Alisha Wahl; Malena Anders; Angelo Armandi; Yvonne Huber; Peter R Galle; Martin Sprinzl; Jörn M Schattenberg
Journal:  AIDS       Date:  2022-07-08       Impact factor: 4.632

4.  Effect of hepatic steatosis and associated metabolic comorbidities on health-related quality of life in people living with HIV.

Authors:  Maurice Michel; Christian Labenz; Malena Anders; Alisha Wahl; Lisann Girolstein; Leonard Kaps; Wolfgang M Kremer; Yvonne Huber; Peter R Galle; Martin Sprinzl; Jörn M Schattenberg
Journal:  Hepatol Commun       Date:  2022-04-12
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.